MRC Economic Impact Report
The MRC Economic Impact Report (formerly known as the Economic Impact Reporting Framework or EIRF) report contains information requested by the government on selected aspects of the organisation’s performance. Economic Impact Reports were introduced across the research councils in 2005, and form part of the performance management framework implemented by the Department for Business, Innovation and Skills (BIS).
The Economic Impact Report contains information on selected aspects of MRC's performance relevant to the Government's objectives for the UK science base. Reporting the economic and social dimensions of research council output has been significantly expanded since 2008/09. Additional metrics and information have been added in consultation with BIS and all research councils. The aim is to make reporting across the councils more consistent and to provide more informative and robust metrics.
The MRC Economic Impact Report shows data for 2007/08, 2008/09, 2009/10 and 2010/11 where possible.
This report should be read in conjunction with the MRC Annual Report, the MRC Annual Review and the annual summary of MRC e-Val data which provide a comprehensive summary of achievements over the period.
Successes reported for 2010/11 include:
o Analysis of 20,000 peer-reviewed papers produced by MRC-funded research groups between 2006 and 2009 demonstrated that these papers have more than twice the world average citation impact (2.17 times). UK papers in biological sciences or clinical and health-related disciplines typically have a citation impact of 1.5 times the world average.
o MRC-funded research has led to over 40 new products and interventions reaching the market between 2006 and 2010, including new equipment for research, new genetic tests, and monoclonal antibody drugs licensed for nine separate conditions.
o MRC funded research has lead to the development of a quick new screening technique for bowel cancer called Flexiscope, this test has been adopted by the UK National Screening Programme and begun a four-year roll out and it is estimated to save around 3,000 lives a year.
o Monoclonal antibody drugs with a link to MRC research are improving the lives of patients suffering from rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease, paroxysmal nocturnal haemoglobinuria, multiple sclerosis, and age-related macular degeneration.
In detail
- Read the 2010/11 Economic Impact Report
- Read the 2009/10 Economic Impact Reporting Framework
- Read the 2008/09 Economic Impact Reporting Framework Data
- Read the 2007/08 Annual Economic Impact Reporting Framework
- Read the 2006/07 Outputs Framework
- Read the 2005/06 Outputs Framework
- Read other Research Councils Outputs Frameworks on the RCUK website
- The DIUS annual report on Outputs Frameworks